-
Delandistrogene moxeparvovec, sold
under the
brand name
Elevidys, is a
recombinant gene
therapy used for the
treatment of
Duchenne muscular dystrophy....
-
address the root
cause are
currently available including gene
therapy (
Elevidys), and
antisense drugs (Ataluren,
Eteplirsen etc.).
Other medications used...
-
address the root
cause are
currently available including gene
therapy (
Elevidys), and
antisense drugs (Ataluren,
Eteplirsen etc.).
Other medications used...
- development, and
commercialization outside of USA, for SRP-9001. In June 2023,
ELEVIDYS (Delandistrogene moxeparvovec) was
approved by the FDA for use in 4-5 year...
-
address the root
cause are
currently available including gene
therapy (
Elevidys).
Other medications used
include glucocorticoids (Deflazacort, Vamorolone);...
- with good results. In June 2023, the FDA gave an
accelerated approval to
Elevidys for
Duchenne muscular dystrophy (DMD) only for boys 4 to 5
years old as...
- BEQVEZ. 20 May 2024.
Retrieved 3
December 2024. "
ELEVIDYS". FDA -
Approved Gene
Therapy Products -
ELEVIDYS. 3
January 2025.
Archived from the
original on...
- (Carvykti):
treatment for
multiple myeloma Delandistrogene moxeparvovec (
Elevidys):
treatment for
Duchenne muscular dystrophy Elivaldogene autotemcel (Skysona):...
- Summit. In 2024,
Marks overruled FDA
staff to
approve gene
pharmacotherapy Elevidys—intended to
treat Duchenne muscular dystrophy—despite it
failing in Phase...
-
Eldecort Eldepryl eledoisin (INN)
Elestat elesclomol eletriptan (INN)
Elevidys Elfabrio elfazepam (INN)
elgodipine (INN)
Elidel Eligard eliglustat (USAN)...
